Ola Landgren
#121,029
Most Influential Person Now
Researcher
Ola Landgren's AcademicInfluence.com Rankings
Ola Landgrenphilosophy Degrees
Philosophy
#5483
World Rank
#8299
Historical Rank
Logic
#2754
World Rank
#3789
Historical Rank
Ola Landgrenbiology Degrees
Biology
#7350
World Rank
#10259
Historical Rank
Immunology
#397
World Rank
#412
Historical Rank
Download Badge
Philosophy Biology
Why Is Ola Landgren Influential?
(Suggest an Edit or Addition)Ola Landgren's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (2014) (2949)
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. (2016) (1536)
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. (2009) (923)
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management (2010) (660)
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. (2015) (532)
- Solid cancers after allogeneic hematopoietic cell transplantation. (2009) (395)
- Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. (2009) (347)
- Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. (2007) (329)
- Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients (2015) (325)
- International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. (2014) (318)
- Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. (2007) (306)
- Racial disparities in incidence and outcome in multiple myeloma: a population-based study. (2010) (298)
- Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group (2013) (289)
- Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. (2005) (286)
- B-cell clones as early markers for chronic lymphocytic leukemia. (2009) (275)
- Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population‐based study of U.S. veterans (2009) (273)
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. (2015) (259)
- Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. (2008) (235)
- Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992–2004 (2009) (231)
- Population‐based study of autoimmune conditions and the risk of specific lymphoid malignancies (2009) (231)
- Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology (2007) (226)
- Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. (2011) (223)
- Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up (2014) (222)
- Risks of myeloid malignancies in patients with autoimmune conditions (2009) (221)
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study (2020) (212)
- Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. (2011) (209)
- Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management (2010) (205)
- Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. (2008) (203)
- Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. (2006) (200)
- Control of autophagic cell death by caspase-10 in multiple myeloma. (2013) (200)
- Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis (2009) (191)
- IMWG consensus on maintenance therapy in multiple myeloma. (2012) (191)
- Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. (2009) (188)
- Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. (2012) (185)
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. (2011) (175)
- Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). (2011) (173)
- Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). (2019) (165)
- Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. (2010) (165)
- Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. (2008) (162)
- A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients (2017) (161)
- Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. (2007) (158)
- Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. (2008) (154)
- Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis (2016) (153)
- Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma (2018) (149)
- Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. (2009) (148)
- Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. (2009) (145)
- Autoimmunity and the risk of myeloproliferative neoplasms (2010) (144)
- Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin’s lymphomas among relatives of patients with chronic lymphocytic leukemia (2009) (140)
- Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population‐based case‐control study (2006) (139)
- Smoldering multiple myeloma. (2015) (133)
- Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. (2009) (131)
- Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey (2014) (129)
- Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964–2003 (2007) (127)
- Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma (2016) (127)
- Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes (2017) (126)
- Improved long-term survival in multiple myeloma up to the age of 80 years (2014) (124)
- Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. (2008) (124)
- Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. (2010) (121)
- Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans (2011) (119)
- Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. (2003) (119)
- Second malignancies after multiple myeloma: from 1960s to 2010s. (2012) (115)
- Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. (2007) (112)
- Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS (2013) (111)
- Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. (2014) (110)
- Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. (2009) (109)
- Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. (2014) (109)
- Hematopoietic Malignancies Associated with Viral and Alcoholic Hepatitis (2008) (109)
- Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study (2012) (109)
- NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. (2019) (107)
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma (2014) (106)
- Cancer Incidence among Pesticide Applicators Exposed to Permethrin in the Agricultural Health Study (2008) (105)
- Autoimmunity and lymphomagenesis (2009) (105)
- Minimal residual disease in multiple myeloma: bringing the bench to the bedside (2015) (105)
- Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis (2007) (105)
- MYD88 L265P somatic mutation in IgM MGUS. (2012) (104)
- Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. (2015) (104)
- Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms (2018) (103)
- Highly increased familial risks for specific lymphoma subtypes (2009) (103)
- Circulating serum free light chains as predictive markers of AIDS-related lymphoma. (2010) (103)
- Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. (2011) (103)
- Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. (2010) (99)
- Different biology and clinical outcome according to the absolute numbers of clonal B‐cells in monoclonal B‐cell lymphocytosis (MBL) (2010) (99)
- Immunologic and Virologic Predictors of AIDS-Related Non-Hodgkin Lymphoma in the Highly Active Antiretroviral Therapy Era (2009) (99)
- Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. (2009) (96)
- Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. (2003) (96)
- Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study (2013) (95)
- The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma. (2015) (94)
- Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study (2009) (94)
- Trends and Racial/Ethnic Disparities in Gluten-Sensitive Problems in the United States: Findings from the National Health and Nutrition Examination Surveys From 1988 to 2012 (2015) (93)
- Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. (2013) (92)
- Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. (2010) (90)
- Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases. (2006) (87)
- A prospective comparison of fine-needle aspiration cytology and histopathology in the diagnosis and classification of lymphomas. (2004) (87)
- Cancer risk among patients with myotonic muscular dystrophy. (2011) (86)
- New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma (2016) (85)
- Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival (2018) (81)
- Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma” (2013) (78)
- MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. (2017) (77)
- Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. (2012) (77)
- Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial (2018) (76)
- From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early Intervention (2011) (76)
- Timing the initiation of multiple myeloma (2019) (76)
- Patterns of hematologic malignancies and solid tumors among 37,838 first‐degree relatives of 13,896 patients with multiple myeloma in Sweden (2009) (75)
- Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973–2003 in Sweden (2009) (75)
- Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection. (2009) (74)
- Environmental pollution and delivery outcome in southern Sweden: a study with central registries (1996) (74)
- Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits (2015) (74)
- Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study (2018) (72)
- Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. (2009) (72)
- Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. (2011) (72)
- Inherited genetic susceptibility to multiple myeloma (2014) (71)
- The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications (2017) (71)
- Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. (2013) (71)
- Second primary malignancies in multiple myeloma: an overview and IMWG consensus. (2016) (69)
- Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. (2006) (68)
- Autoimmunity and hematologic malignancies: associations and mechanisms (2009) (67)
- A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma (2004) (67)
- The Kinetics and Reproducibility of 18F-Sodium Fluoride for Oncology Using Current PET Camera Technology (2012) (67)
- Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. (2014) (66)
- Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia (2009) (66)
- High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. (2005) (66)
- Familial Aggregation and Heterogeneity of Non-Hodgkin Lymphoma in Population-Based Samples (2005) (66)
- Thrombosis is associated with inferior survival in multiple myeloma (2012) (65)
- Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination Survey (2017) (64)
- Accuracy of ICD-9-CM codes in identifying infections of pneumonia and herpes simplex virus in administrative data. (2013) (63)
- Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population‐based study of 1,555 patients diagnosed in Sweden from 1980 to 2005 (2013) (62)
- Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance (2014) (61)
- Acquired immune‐related and inflammatory conditions and subsequent chronic lymphocytic leukaemia (2007) (60)
- A prospective study of circulating adipokine levels and risk of multiple myeloma. (2012) (60)
- Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. (2011) (60)
- Procedure‐related pain among adult patients with hematologic malignancies (2009) (59)
- CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. (2020) (58)
- The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies (2015) (57)
- Chronic immune stimulation and subsequent Waldenström macroglobulinemia. (2008) (57)
- Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis (2010) (57)
- Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease. (2000) (56)
- Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. (2019) (56)
- Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA‐NCI roundtable symposium (2014) (55)
- Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) (2020) (54)
- Risk of Multiple Myeloma following Medication Use and Medical Conditions: A Case-Control Study in Connecticut Women (2006) (54)
- Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms. (2019) (53)
- Risk of myeloid neoplasms after solid organ transplantation (2014) (53)
- Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. (2018) (52)
- A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. (2016) (52)
- Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation (2017) (51)
- Multiple myeloma precursor disease. (2010) (51)
- Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. (2019) (51)
- Revealing the impact of structural variants in multiple myeloma. (2020) (51)
- Increased levels of circulating cytokines with HIV-related immunosuppression. (2012) (51)
- A population‐based assessment of mortality and morbidity patterns among patients with thymoma (2011) (50)
- CAR T cell therapy for multiple myeloma: where are we now and where are we headed? (2018) (50)
- Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat (2015) (49)
- Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. (2018) (48)
- Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study. (2015) (48)
- Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688) (2019) (47)
- New aspects in descriptive, etiologic, and molecular epidemiology of Hodgkin's lymphoma. (2007) (47)
- Myeloma and second primary cancers. (2011) (47)
- Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities (2021) (47)
- Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients. (2007) (46)
- Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin's lymphoma in veterans from the United States. (2011) (46)
- Prior Autoimmune Disease and Risk of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Systematic Review (2014) (46)
- Risk of second malignant neoplasms among lymphoma patients with a family history of cancer (2006) (46)
- The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies (2015) (45)
- Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia. (2006) (45)
- Current Insight on Trends, Causes, and Mechanisms of Hodgkin’s Lymphoma (2009) (45)
- Prevalence of monoclonal B‐cell lymphocytosis: A systematic review (2010) (45)
- Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma (2020) (44)
- Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. (2012) (44)
- Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity (2013) (44)
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma (2021) (43)
- How I treat smoldering multiple myeloma. (2014) (43)
- Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma (2020) (42)
- Risk of malignant disease among 1525 adult male US Veterans with Gaucher disease. (2007) (42)
- Second primary malignancies in multiple myeloma: an overview and IMWG consensus. (2018) (42)
- Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients (2013) (42)
- Common genetic variants in candidate genes and risk of familial lymphoid malignancies (2009) (41)
- Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years (2015) (41)
- Increased Risk for Lymphoid and Myeloid Neoplasms in Elderly Solid-Organ Transplant Recipients (2010) (41)
- BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy (2019) (41)
- Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. (2019) (41)
- Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study (2019) (40)
- Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial. (2021) (40)
- Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial. (1995) (38)
- Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. (2017) (38)
- Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends (2016) (38)
- Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study (2016) (38)
- Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. (2019) (37)
- Bortezomib to treat the TEMPI syndrome. (2012) (36)
- Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient (2016) (36)
- Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. (2015) (36)
- Plasma Cell Neoplasms in US Solid Organ Transplant Recipients (2013) (34)
- Autoimmunity and risk for Hodgkin’s lymphoma by subtype (2009) (34)
- Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients (2011) (34)
- Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma (2019) (34)
- Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes. (2012) (34)
- Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies (2021) (34)
- COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers (2020) (34)
- Current and future imaging modalities for multiple myeloma and its precursor states (2011) (33)
- MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. (2016) (33)
- Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies (2009) (33)
- Increased incidence of chronic lymphocytic leukaemia and lymphomas in patients with Merkel cell carcinoma – a population based study of 335 cases with neuroendocrine skin tumour (2012) (33)
- Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster (2018) (33)
- Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management (2011) (32)
- Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. (2014) (32)
- Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma (2019) (32)
- COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers (2020) (32)
- Chronic lymphocytic leukaemia genetics overview (2007) (32)
- Biological determinants of health disparities in multiple myeloma (2018) (31)
- Pain and anxiety during bone marrow aspiration/biopsy: Comparison of ratings among patients versus health-care professionals. (2012) (31)
- A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma (2015) (31)
- Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases (2007) (31)
- Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial (2018) (31)
- Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM (2014) (31)
- Familial Aspects of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and Related Lymphomas. (2010) (30)
- Update on second primary malignancies in multiple myeloma: a focused review (2014) (30)
- Hodgkin Lymphoma Among US Solid Organ Transplant Recipients (2010) (30)
- Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. (2017) (30)
- Comparison of MALDI‐TOF mass spectrometry analysis of peripheral blood and bone marrow‐based flow cytometry for tracking measurable residual disease in patients with multiple myeloma (2020) (30)
- Accelerated single cell seeding in relapsed multiple myeloma (2020) (30)
- Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. (2017) (30)
- MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment. (2018) (30)
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. (2021) (29)
- Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals. (2016) (29)
- Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice (2013) (28)
- Immune thrombocytopenic purpura does not exhibit a disparity in prevalence between African American and White veterans. (2006) (28)
- Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology. (2010) (28)
- Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma (2019) (28)
- Novel aspects pertaining to the relationship of Waldenström's macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia. (2009) (28)
- Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma. (2018) (27)
- Shall we treat smoldering multiple myeloma in the near future? (2017) (27)
- Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients (2019) (27)
- Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973–2001, a population‐based study (2010) (26)
- Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma (2010) (26)
- Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial (2014) (26)
- TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms (2014) (26)
- Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation (2017) (25)
- MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool. (2018) (25)
- Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging (2016) (25)
- Risks of cancer among a cohort of 23,935 men and women with osteoporosis (2007) (25)
- Timing of births and endometrial cancer risk in Swedish women (2009) (25)
- Mantle cell lymphomas with clonal immunoglobulin VH3–21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin VH genes (2005) (25)
- Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients (2012) (24)
- Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study (2017) (24)
- Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome (2010) (24)
- No familial aggregation in chronic myeloid leukemia. (2013) (24)
- The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma (2017) (24)
- Response to splenectomy is durable after a certain point in time in adult patients with chronic immune thrombocytopenic purpura (2006) (23)
- B-cell maturation antigen expression across hematologic cancers: a systematic literature review (2020) (23)
- The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma (2014) (23)
- Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future. (2010) (23)
- Population-based study on the impact of the familial form of Waldenström macroglobulinemia on overall survival. (2015) (23)
- Appearance of monoclonal plasma cell diseases in whole‐body magnetic resonance imaging and correlation with parameters of disease activity (2014) (23)
- Second malignancies in multiple myeloma; emerging patterns and future directions. (2020) (22)
- Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. (2021) (22)
- Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study (2016) (22)
- MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients (2016) (21)
- Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay. (2019) (21)
- Increased mortality among men aged 50 years old or above with elevated IgA anti-transglutaminase antibodies: NHANES III (2016) (21)
- Circulating Antibody Free Light Chains and Risk of Posttransplant Lymphoproliferative Disorder (2012) (21)
- Quantifying Cancer Absolute Risk and Cancer Mortality in the Presence of Competing Events after a Myotonic Dystrophy Diagnosis (2013) (21)
- Molecular imaging in myeloma precursor disease. (2011) (21)
- A method to visualize and adjust for selection bias in prevalent cohort studies. (2011) (21)
- Dilemmas in treating smoldering multiple myeloma. (2015) (21)
- Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method (2015) (21)
- Familial Aggregation of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia with Solid Tumors and Myeloid Malignancies (2012) (20)
- A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM) (2019) (20)
- Pursuing the curative blueprint for early myeloma. (2013) (20)
- Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (2021) (20)
- Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. (2019) (20)
- Fractures and survival in multiple myeloma: results from a population-based study (2019) (20)
- Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma (2019) (20)
- Risk profile and outcome in Hodgkin's lymphoma: is obesity beneficial? (2005) (20)
- Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study. (2017) (20)
- MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström’s Macroglobulinemia (2014) (20)
- Prior history of non-melanoma skin cancer is associated with increased mortality in patients with chronic lymphocytic leukemia (2009) (19)
- Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma (2019) (19)
- Evolving therapeutic paradigms for multiple myeloma: back to the future (2013) (19)
- Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (2014) (19)
- Use of hair colouring products and risk of multiple myeloma among US women (2008) (19)
- History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study (2016) (19)
- Circulating cytokine levels, Epstein‐Barr viremia, and risk of acquired immunodeficiency syndrome‐related non‐Hodgkin lymphoma (2011) (19)
- MGUS prevalence in an ethnically Chinese population in Hong Kong. (2013) (19)
- Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance (2009) (19)
- Meeting report: Advances in minimal residual disease testing in multiple myeloma 2018 (2019) (19)
- Prevalence, clinical aspects, and natural history of IgM MGUS (2010) (18)
- The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift? (2020) (18)
- Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma (2020) (18)
- Myeloma minimal residual disease testing in the United States: Evidence of improved standardization (2016) (18)
- Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities. (2011) (18)
- The mutagenic impact of melphalan in multiple myeloma (2021) (18)
- GPRC5D-Targeted CAR T Cells for Myeloma. (2022) (18)
- Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden (2012) (17)
- Improved Survival in AL Amyloidosis: A Population-Based Study on 1,430 Patients Diagnosed in Sweden 1995-2013 (2016) (17)
- Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans (2011) (17)
- Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma (2012) (17)
- Minimal residual disease: what are the minimum requirements? (2014) (17)
- Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance. (2011) (17)
- Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity. (2020) (17)
- Common community‐acquired infections and subsequent risk of multiple myeloma: A population‐based study (2014) (16)
- Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma. (2011) (16)
- Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease (2017) (16)
- Personal and family history of autoimmune diabetes mellitus and susceptibility to young‐adult‐onset Hodgkin lymphoma (2006) (16)
- CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. (2016) (16)
- Survival patterns in patients with Hodgkin's lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease. (2010) (16)
- Survival patterns among lymphoma patients with a family history of lymphoma. (2008) (16)
- Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease. (2014) (16)
- Genetics- and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/ Waldenström's macroglobulinemia. (2009) (16)
- Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity (2018) (16)
- Plasma Markers of B-Cell Activation and Clonality in Pediatric Liver and Hematopoietic Stem Cell Transplant Recipients (2013) (16)
- Mass spectrometry-based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma. (2020) (15)
- Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. (2019) (15)
- Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities (2014) (15)
- Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM (2017) (15)
- Risk of Arterial and Venous Thrombosis in 11,155 Patients with Myeloproliferative Neoplasms and 44,620 Matched Controls; A Population-Based Study (2014) (14)
- Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases (2013) (14)
- Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration (2021) (14)
- Monoclonal gammopathy‐associated pure red cell aplasia (2016) (14)
- A Benefit–Risk Analysis Approach to Capture Regulatory Decision‐Making: Multiple Myeloma (2018) (14)
- Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma (2014) (14)
- Re: Familial clustering of Hodgkin lymphoma and multiple sclerosis. (2005) (14)
- Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma (2018) (14)
- Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models. (2020) (13)
- Hodgkin lymphoma risk following infectious and chronic inflammatory diseases: a large population-based case–control study from Sweden (2015) (13)
- Dietary intake is associated with risk of multiple myeloma and its precursor disease (2018) (13)
- Multiple myeloma: is it time for biomarker-driven therapy? (2015) (13)
- Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study (2020) (13)
- Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms (2018) (13)
- The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study. (2016) (13)
- Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study (2016) (13)
- Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients (2016) (13)
- A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients. (2006) (13)
- Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies. (2014) (13)
- Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia. (2013) (13)
- Isotype-Specific Heavy/Light Chain (HLC) Suppression as a Predictor of Myeloma Development in Monoclonal Gammopathy of Undetermined Significance (MGUS). (2009) (13)
- Host-related immunodeficiency in the development of multiple myeloma (2018) (12)
- Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis. (2020) (12)
- Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. (2016) (12)
- Infiltration patterns in monoclonal plasma cell disorders: correlation of magnetic resonance imaging with matched bone marrow histology. (2014) (12)
- Preclinical development and First-in-human imaging of 89Zr-Daratumumab for CD38 targeted imaging of myeloma (2019) (12)
- Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing (2020) (12)
- Brain tumors in patients with myotonic dystrophy: a population‐based study (2016) (12)
- Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. (2021) (12)
- mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies (2021) (12)
- Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma (2020) (12)
- Epidemiology, pathology and treatment of non-follicular indolent lymphomas (2008) (11)
- Chromothripsis as a pathogenic driver of multiple myeloma. (2021) (11)
- Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time. (2019) (11)
- The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma (2015) (11)
- Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. (2022) (11)
- Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma (2021) (11)
- Multiple myeloma precursor disease: current clinical and epidemiological insights and future opportunities. (2011) (11)
- Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study (2018) (11)
- Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone (2017) (10)
- Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals. (2012) (10)
- BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we? (2007) (10)
- Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events. (2021) (10)
- Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors. (2019) (10)
- Multiple myeloma precursor disease: current clinical dilemma and future opportunities. (2011) (10)
- Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma (2018) (10)
- PLASMA CELL LEUKEMIA : Consensus Statement on Diagnostic Requirements , Response Criteria , and Treatment Recommendations by the International Myeloma Working Group ( IMWG ) (2014) (10)
- Perspectives on the Risk-Stratified Treatment of Multiple Myeloma (2022) (10)
- High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster (2019) (10)
- Routine bone scintigraphy is of limited value in the clinical assessment of untreated patients with Hodgkin's disease (2000) (9)
- Parental longevity and survival in elderly patients with Hodgkin's lymphoma. (2002) (9)
- A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor. (2019) (9)
- Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency* (2017) (9)
- Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM) (2018) (9)
- High prevalence of polyclonal hypergamma‐globulinemia in adult males in Ghana, Africa (2011) (9)
- Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study (2014) (9)
- Infection in infancy and subsequent risk of developing lymphoma in children and young adults. (2011) (9)
- [Imaging in smoldering (asymptomatic) multiple myeloma. Past, present and future]. (2014) (9)
- Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. (2019) (9)
- Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression (2012) (9)
- Delivery outcome in pregnancies when either parent worked in the chemical industry. A study with central registries. (1994) (9)
- Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders. (2020) (9)
- Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms (2009) (9)
- Parental longevity and prognosis in elderly patients with aggressive non-hodgkin's lymphoma (2004) (8)
- Survival in patients with familial and sporadic myeloproliferative neoplasms. (2015) (8)
- Over 30% of Smoldering Myeloma Patients Have Tumor Cell Bone Marrow Infiltration Patterns Similar to Multiple Myeloma: A Large (n=544) Clinical Study Using Whole-Body MRI. (2012) (8)
- Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system (2012) (8)
- Analysis of VDT-PACE Utilization in Multiple Myeloma Patients Treated at MSKCC for Relapsed Disease or Cytoreduction and Stem Cell Mobilization after Initial Induction Therapy (2014) (8)
- Positive selection as the unifying force for clonal evolution in multiple myeloma (2021) (8)
- What causes Waldenström's macroglobulinemia: genetic or immune-related factors, or a combination? (2011) (8)
- Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy (2015) (8)
- Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditions. (2013) (8)
- Lifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective Cohort of Male Farmers (2021) (8)
- Comorbidities in multiple myeloma and implications on survival: A population‐based study (2021) (8)
- Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study (2019) (7)
- Monoclonal B cell lymphocytosis: Clinical and population perspectives (2010) (7)
- Development of early treatment strategies for high-risk myeloma precursor disease in the future. (2011) (7)
- Multiple myeloma and second malignancies. (2014) (7)
- Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity 1 with Novel Induction Regimens in Multiple Myeloma. (2020) (7)
- Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience (2021) (7)
- Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapy (2021) (7)
- Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma. (2019) (7)
- Pre-salvage ISS and Other Important Outcome Associations in CD34 Selected Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma. (2020) (7)
- VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis (2019) (7)
- Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age (2013) (7)
- Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. (2009) (7)
- Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma: a prospective study (2009) (7)
- Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment (2020) (7)
- Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study (2020) (7)
- Treating myeloma: the future is already here! (2012) (7)
- Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls. (2020) (6)
- MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone (2018) (6)
- Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients (2018) (6)
- HIV, EBV, and monoclonal gammopathy. (2013) (6)
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states (2022) (6)
- Proteomic profiling in plasma cell disorders: a feasibility study (2017) (6)
- Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study (2021) (6)
- Serum Heavy-Light Chains (HLC) and Free Light Chains (FLC) As Predictors For Early CR In Newly Diagnosed Myeloma Patients Treated With Carfilzomib, Lenalidomide, and Dexamethasone (CRd) (2013) (6)
- FAMILIAL LONGEVITY: THE OLDER YOU ARE, THE OLDER YOUR FATHER MAY HAVE BEEN (2005) (6)
- Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study (2016) (6)
- Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma (2021) (6)
- Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials (2014) (6)
- Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia. (2016) (6)
- Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma. (2020) (6)
- Increased Risks of Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Myelofibrosis (MF) among 24577 First-Degree Relatives of 11039 Patients with Chronic Myeloproliferative Disorders (MPD) in Sweden. (2007) (6)
- Incidence and Management of Proteasome Inhibitor-Related Cardiotoxicity in Multiple Myeloma Patients at Memorial Sloan Kettering Cancer Center (2015) (6)
- A role for ionizing radiation in myelomagenesis? (2009) (6)
- Pesticide Use and Kidney Function Among Farmers in the Biomarkers of Exposure and Effect in Agriculture Study. (2021) (5)
- Novel Therapies in Multiple Myeloma for Newly Diagnosed Nontransplant Candidates (2009) (5)
- Revealing the impact of recurrent and rare structural variants in multiple myeloma (2019) (5)
- Multiple Myeloma and Infections: A Population-Based Study Based On 9,610 Multiple Myeloma Patients (2012) (5)
- Smoldering multiple myeloma: present position and potential promises (2014) (5)
- Early Myelodysplastic Changes Present in Substantial Proportion of Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Patients (2012) (5)
- Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length (2021) (5)
- Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide (2019) (5)
- The road to treating smoldering multiple myeloma. (2014) (5)
- A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma (2011) (5)
- Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial. First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study (2021) (5)
- patients: a population-based study in Sweden lymphoplasmacytic lymphoma/Waldenström macroglobulinemia Risk of lymphoproliferative disorders among first-degree relatives of (2013) (5)
- Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms (2017) (5)
- Whole genome sequencing provides evidence of two biologically and clinically distinct entities of asymptomatic monoclonal gammopathies: progressive versus stable myeloma precursor condition (2020) (5)
- Associations between multiple myeloma and other malignancies (2011) (5)
- Improved patient survival for acute myeloid leukemia: A population-based study of 9,729 patients diagnosed in Sweden 1973-2005 Running title: Survival in acute myeloid leukemia (2008) (5)
- Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets (2022) (5)
- Bone Marrow-Based and Longitudinal Blood-Based MRD Tracking in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd): A Correlative and Clinical Phase II Study (2018) (5)
- Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study (2021) (5)
- Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study (2022) (4)
- Revealing the Impact of Recurrent and Rare Structural Variations in Multiple Myeloma (2019) (4)
- Patterns of Survival and Causes of Death In 9,384 Patients with Myeloproliferative Neoplasms Diagnosed In Sweden Between 1973 and 2008 (2010) (4)
- Associations between non-Hodgkin lymphoma and renal cell carcinoma (2011) (4)
- Disease anticipation in familial myeloproliferative neoplasms. Authors' reply (2008) (4)
- Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study (2022) (4)
- Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance (2020) (4)
- Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone (2021) (4)
- Molecular Cytogenetic Approach to the Diagnosis of Splenic Lymphoma: A Case Report of Blastoid Mantle Cell Lymphoma (2003) (4)
- The Long PD-1 Receptor Binding Kinetics of Nivolumab May Increase Efficacy of Subsequent Therapy in Relapsed and Refractory Multiple Myeloma Patients (2015) (4)
- Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls (2019) (4)
- A new era of novel immunotherapies for multiple myeloma (2021) (4)
- Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients. (2016) (4)
- African-American Multiple Myeloma Patients Have a Better Survival Than Caucasian Patients: a Population-Based Study Including 28,636 Patients. (2009) (4)
- Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001 (2020) (4)
- Risk of Hepatobiliary and Pancreatic Cancers Following Hepatitis C Virus Infection (2010) (4)
- Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma (2021) (4)
- Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance (2020) (4)
- Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance (2017) (4)
- T-Cell Engagers - Modern Immune-Based Therapies for Multiple Myeloma. (2022) (4)
- The Success Story of Targeted Therapy In Chronic Myeloid Leukemia A Population Based Study of 3,173 Patients Diagnosed In Sweden 1973-2008 (2010) (4)
- Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study (2020) (4)
- Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. (2021) (4)
- Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) Study (2021) (4)
- Capture Rate of the Adaptive Next Generation Sequencing VDJ Assay in Multiple Myeloma (2018) (3)
- Shared susceptibility for celiac disease and inflammatory bowel disease? (2008) (3)
- Management of multiple myeloma during COVID-19 pandemic (2020) (3)
- WT1 heteroclitic epitope immunization following autologous stem cell transplantation in patients with high-risk multiple myeloma (MM). (2017) (3)
- Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma (2020) (3)
- No Risk of Arterial or Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance: Results from a Population-Based Study (2015) (3)
- Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma (2021) (3)
- A Phase II Trial of AZD 6244 ( Selumetinib , ARRY-142886 ) , an Oral MEK 1 / 2 Inhibitor , in Relapsed / Refractory Multiple Myeloma (2015) (3)
- Identifying Ultra-High Risk Smoldering Multiple Myeloma (2018) (3)
- Family history of venous thromboembolism is associated with increased risk for thrombosis in multiple myeloma: a population‐based study (2012) (3)
- A Phase II Trial of IPH2101 (anti-KIR mAb) in Smoldering Multiple Myeloma (2011) (3)
- Response: Multiple myeloma is universally preceded by a prolonged premalignant stage: novel clinical insights and future directions (2009) (3)
- Elevated Risk of Venous but Not Arterial Thrombosis in Waldenström's Macroglobulinemia and Lymphoplasmacytic Lymphoma (2012) (3)
- Myeloma imaging: time to move on! (2016) (3)
- Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma (2015) (3)
- Peripheral Neuropathy Is an Under-Recognized Feature of Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study of 18,668 MGUS Patients and Their 97,641 Matched Controls (2017) (3)
- Nutrition perceptions, needs and practices among patients with plasma cell disorders (2022) (3)
- Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. (2020) (3)
- Genomic and Immune Signatures Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd) (2021) (3)
- Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study (2019) (3)
- A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre‐ibrutinib era (2020) (3)
- Serum free light chains as predictors of lymphomagenesis in patients with autosomal dominant hyper-immunoglobulin E syndrome (Job's syndrome) (2013) (3)
- Deep vein thrombosis following monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (2008) (3)
- Depth of Response and Outcomes in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation (2018) (3)
- Role of immune-related conditions in smoldering myeloma and MGUS. (2012) (3)
- Hevylite™ Assays Detect a Hidden Immunoparesis Associated with Adverse Biology in Myeloma Precursor Disease: A Prospective Clinical Study (2011) (3)
- Thromboprophylaxis in multiple myeloma: is the evidence there? (2012) (3)
- Abstract 5231: Multiple myeloma will become a common cancer in the era of modern therapy (2016) (3)
- Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms (2017) (3)
- Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis (2019) (3)
- P-042: Sustained minimal residual disease negativity in Multiple Myeloma is impacted positively by stool butyrate and healthier plant forward diets (2021) (2)
- Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population‐based cohort study (2021) (2)
- Sun, mother of life, prevents cancer. (2011) (2)
- Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy. (2021) (2)
- Next Generation Sequencing (NGS) Based IGH and TCR Clonality Assays Provide Excellent Specificity and Sensitivity for Routine Clonal Characterization and Monitoring of Lymphoproliferative Disorders (2017) (2)
- Increased Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Lymphoproliferative Tumors among 14689 First-Degree Relatives of 4488 MGUS Patients in Sweden. (2007) (2)
- Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With Cancer. (2022) (2)
- Evaluation Of Circulating Cell-Free VDJ DNA As a Marker For Monitoring Patients With Multiple Myeloma (MM) During Treatment With Carfilzomib, Lenalidomide and Dexamethasone, (2013) (2)
- A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up (2018) (2)
- Author Correction: Accelerated single cell seeding in relapsed multiple myeloma (2021) (2)
- Genetics in Lymphomagenesis (2013) (2)
- Mytype targeted next generation sequencing assay for detection of igh translocations and copy number alterations in multiple myeloma (2018) (2)
- Pesticide Use and Kidney Function among Pesticide Applicators in the Biomarkers of Exposure and Effect in Agriculture Study (2019) (2)
- MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy (2019) (2)
- Influence of Aging Processes on the Biology and Outcome of Multiple Myeloma (2020) (2)
- Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma (2018) (2)
- Whole-Genome Sequencing Reveals Evidence of Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Myeloma Precursor Disease (2020) (2)
- A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone (wKRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM) (2019) (2)
- PS2-22: Accuracy of Diagnostic Codes to Identify Rheumatoid Arthritis in Archived Electronic Health System Data: Support for Future Cancer Research Network Studies of Lymphoma Risk Pathways (2013) (2)
- Contribution photo (2016) (2)
- MGUS prevalence in a cohort of AML patients. (2013) (2)
- A091 Incidence of Myeloma Over 56 Years (1950–2006): A Population-Based Study from Malmö, Sweden (2009) (2)
- Serum immunoglobulin free light chains and post-transplant lymphoproliferative disorder among allogeneic hematopoietic stem cell transplant recipients (2015) (2)
- Racial/ethnic disparities: need more work! (2017) (2)
- Prevalence of Type 1 Gaucher Disease in the United States—Reply (2008) (2)
- A Population-Based Study of Incidence of Myeloproliferative Neoplasms in Sweden Between 2000 and 2012 (2015) (2)
- No CLL transmission through blood transfusion. (2015) (2)
- Patterns of Infectious Morbidity in Patients with Waldenström’s Macroglobulinaemia/Lymphoplasmacytic Lymphoma: A Population-Based Study (2014) (2)
- Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study (2020) (2)
- Prognosis in Acute Myeloid Leukemia: A Population-Based Study on 5,809 Patients Diagnosed in Sweden 1973–2001. (2005) (2)
- Molecular underpinnings of clinical disparity patterns in African American (AA) versus Caucasian American (CA) multiple myeloma (MM) patients. (2018) (2)
- Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study (2019) (2)
- Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14) (2021) (2)
- Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (2022) (2)
- Multiple myeloma: Current advances and future directions. (2020) (2)
- P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS (2022) (2)
- Risk of Progression in Monoclonal Gammopathy of Undetermined Significance (MGUS): Results from a Population-Based Screening Study (2016) (2)
- Upfront Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients: An Update on Cost Analysis Study at Memorial Sloan Kettering Cancer Center (2014) (1)
- Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study (2020) (1)
- Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. (2022) (1)
- Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study (2022) (1)
- Pure Red Cell Aplasia Associated with Plasma Cell Myeloma: Does Monoclonal Protein Inhibit Erythropoiesis? (2010) (1)
- Evolution of a precursor (2010) (1)
- Hepatitis C virus infection and risk of post-transplant lymphoproliferative disorder among solid organ transplant recipients (2007) (1)
- Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do (2022) (1)
- A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression (2022) (1)
- Intestinal Microbiota Composition Is Associated with Minimal Residual Disease Negativity in Patients with Multiple Myeloma (2018) (1)
- Comparison of Standard Assays (Serum Immunofixation and Protein Electrophoresis) with Hevylite Assay in Patients with Multiple Myeloma (2016) (1)
- Depth and Timing of Improvement of Response for Multiple Myeloma Patients on Lenalidomide Maintenance after Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) (2017) (1)
- macroglobulinemia (WM) and related disorders: IWWM-7 consensus Treatment recommendations for patients with Waldenström (2014) (1)
- The Majority of Patients with Relapsing Light Chain (AL) Amyloidosis Are Not Eligible for Enrollment Onto Clinical Trials: Using Screen Failures to Define Major Unmet Medical Needs (2015) (1)
- The Genomic Complexity of Multiple Myeloma Precursor Disease Can be Predicted Using Copy Number Signatures on Targeted Sequencing and SNP Array Data (2020) (1)
- Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions. (2022) (1)
- Centaurus (JNJ5467414SMM2001): A Randomized Phase II Trial to Evaluate Three Daratumumab (DARA) Dose Schedules in Smoldering Multiple Myeloma (SMM) (2015) (1)
- T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape (2022) (1)
- Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. (2012) (1)
- Low Intake of Fruits and Vegetables and High Intake of Processed Meats and Juices Are Associated with Risk of MGUS in the National Health and Nutrition Examination Survey (NHANES) Database (2022) (1)
- Risk Factors for Acute Myeloid Leukemia and Myelodysplastic Syndromes in Patients with Multiple Myeloma: An Updated Analysis (2018) (1)
- Early biomarkers of response to carfilzomib in multiple myeloma (MM): Modulation of CXCR4 and induction of autophagy. (2014) (1)
- Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (2014) (1)
- Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. (2020) (1)
- CD81: A Novel, Specific and Highly Sensitive Marker in Flow Cytometric Diagnosis of Plasma Cell Dyscrasia (2011) (1)
- Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study (2022) (1)
- Prognostic Factors for Post-Relapse Survival after ex-vivo CD34+-Selected (T cell-depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. (2020) (1)
- Epidemiology of Waldenström Macroglobulinemia (2017) (1)
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma (2021) (1)
- Imaging Measurable (Minimal) Residual Disease in Multiple Myeloma (2016) (1)
- Galinpepimut-S, a WT1-Targeting Immuno-Oncology Treatment, Induces Specific, Robust and Durable Immune Responses (IRs) in Patients (Pts) with High-Risk (HR) Multiple Myeloma (MM) (2017) (1)
- Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma (2020) (1)
- Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study (2011) (1)
- Epidemiology and Pathophysiology of Multiple Myeloma (2018) (1)
- Sweden lymphoid and myeloid malignancies : 728 cases followed up to 30 years Monoclonal gammopathy of undetermined significance and risk (2013) (1)
- Plasma Circulating Proteasomes As Biomarkers Along Natural History Of Asymptomatic Monoclonal Gammopathies (2013) (1)
- Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001 (2021) (1)
- Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients (2020) (1)
- Improved Patient Survival and Cure for Hodgkin Lymphoma: A Population-Based Study of 6,136 Patients Diagnosed in Sweden 1973-2005. (2009) (1)
- Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin lymphoma in United States veterans (2010) (1)
- Appearance of Monoclonal Plasma Cell Diseases in Whole Body MRI in 544 Patients and Correlation with Parameters of Disease Activity (2012) (1)
- Evidence of Pre-Diagnostic Monoclonality in Blood Obtained up to 6.4 Years Preceding Diagnosis of Chronic Lymphocytic Leukemia (CLL). (2007) (1)
- Genetic and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia (2009) (1)
- Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation (2022) (1)
- Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies (2019) (1)
- Familial Aggregation of Multiple Myeloma and Its Precursor Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study in Sweden (2008) (1)
- Extreme body mass index and survival in newly diagnosed multiple myeloma patients (2023) (1)
- Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms (2021) (1)
- Molecular Evolution of Classical Hodgkin Lymphoma Revealed Though Whole Genome Sequencing of Hodgkin and Reed-Sternberg Cells (2021) (1)
- Induction with Bortezomib and Dexamethasone (BD) Followed By Risk Adapted High Dose Melphalan and Autologous Stem Cell Transplantation and BD Consolidation in Patients with AL Amyloidosis: A Phase II Feasibility Study (2015) (1)
- Structural variants shape the genomic landscape and clinical outcome of multiple myeloma (2022) (1)
- Stem Cell Mobilization and Autograft Purity with Novel Induction Regimens in Multiple Myeloma (2019) (1)
- Estimating Selection Bias in Previous Monoclonal Gammopathy of Undetermined Significance Research - the Importance of Screening: Results from the Population-Based Screening Study Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM) (2021) (1)
- A population‐based study on serious inpatient bacterial infections in patients with chronic lymphocytic leukemia and their impact on survival (2020) (1)
- Response: More on disease anticipation in familial MPN. (2008) (1)
- Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach (2022) (1)
- Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study (2009) (1)
- Response to Splenectomy Is Durable after a Certain Point in Time in Adult ITP Patients. (2005) (1)
- Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM) (2013) (1)
- Interim Analysis of a Randomized Phase II Trial Comparing Continuous Lenalidomide and Dexamethasone to Autologous Stem Cell Transplantation in Multiple Myeloma Patients Responsive to Lenalidomide and Dexamethasone Induction (2014) (1)
- Second Malignant Neoplasms Following Multiple Myeloma: A Cohort Study On 744 Patients Treated 1997-2011 (2013) (1)
- Peripheral Neuropathy in MGUS and Progression to Amyloid Light-Chain Amyloidosis: A Population-Based Study Including 15,351 MGUS Cases (2019) (1)
- Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status. (2016) (1)
- The Mutational and Signaling Landscape of Multiple Myeloma Varies Dependent upon Translocation Cyclin D (TC) Subgroup (2016) (1)
- Chemotherapy Signatures Map Evolution of Therapy-Related Myeloid Neoplasms (2022) (1)
- Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma (2022) (1)
- Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls (2021) (1)
- Re-immunization following Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance (2017) (1)
- Using MALDI-TOF mass spectrometry for tracking of minimal residual disease in peripheral blood from patients with multiple myeloma. (2019) (1)
- A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (2020) (1)
- Evaluating serum-free light chain ratio as a biomarker for multiple myeloma. (2022) (1)
- Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study. (2018) (1)
- Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients with Multiple Myeloma (2019) (1)
- Utility Of An Algorithm For Use Of Plerixafor In Filgrastim-based Hematopoietic Progenitor Cell Mobilization In Patients With Plasma Cell Myeloma Treated With Carfilzomib-Lenalidomide-Dexamethasone. (2013) (0)
- Correction: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies (2023) (0)
- Abstract 6067: Characterizing the landscape of rare structural variant events in newly diagnosed multiple myeloma (2023) (0)
- disorder among solid organ transplant recipients Hepatitis C virus infection and risk of post-transplant lymphoproliferative (2013) (0)
- Germline Genes Specific to Chronic Lymphocytic Leukemia (CLL) and Genes Common to CLL, Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas Are Important in Susceptibility (2008) (0)
- Abstract 4943: Circulating immunologic markers and risk of multiple myeloma and its precursor disease: A nested case-control study (2018) (0)
- MULTIPLE MYELOMA PATIENTS THAT DEVELOP SECOND PRIMARY MALIGNANCY HAVE A WORSE PROGNOSIS THAN MULTIPLE MYELOMA PATIENTS TREATED BEFORE THE INTRODUCTION OF NOVEL AGENTS : A POPULATION BASED-STUDY (2014) (0)
- Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma (2022) (0)
- Peripheral Blood Involvement with Minimal Disease Is Common in Multiple Myeloma but Not in Smoldering Myeloma (2012) (0)
- A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy (2022) (0)
- Temporal Trends in the Proportion Cured Among Patients Diagnosed with Acute Myeloid Leukemia in Sweden 1973-2001, a Population-Based Study. (2009) (0)
- Survival patterns among Hodgkin lymphoma patients with a family history of lymphoma (2007) (0)
- Monoclonal Gammopathy of Undetermined Significance and Risk of Infections A Population Based Study (2010) (0)
- Hormone replacement therapy and risk of multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS) in the UK Clinical Practice Research Datalink (2017) (0)
- Copy Number Signatures Predict Chromothripsis and Poor Clinical Outcome in Newly Diagnosed Multiple Myeloma Patients (2020) (0)
- Abstract 5074: Elevated serum free light chains and risk of non-Hodgkin lymphoma and the subtype follicular lymphoma in a prospective cohort study (2014) (0)
- Why Clinicians are Not Relying on Evidence from Indirect Comparison Studies Evaluating Comparative Efficacy of Interventions for Relapsed or Refractory Multiple Myeloma: A Critical Review: MM‐262 (2018) (0)
- Whole Exome Sequencing from Nine Independent Sites of Extraosseous Disease in a Single Patient with Relapsed Multiple Myeloma Show That Extramedullary Disease Arise through a Combination of Branched and Parallel Evolution (2016) (0)
- Focal bone marrow processes and early bone lesions in patients with multiple myeloma (MM) precursor diseases: A prospective study using molecular imaging. (2014) (0)
- Longitudinal 18 f-FDG-PET-CT Analysis in Newly Diagnosed Multiple Myeloma (NDMM) Patients Following Carfilzomib, Lenalidomide, Dexamethasone Induction and Lenalidomide Maintenance (CRd-R) (2016) (0)
- Abstract 4408: A functional genomics approach for identification of sirolimus sensitizer genes regulated by HDAC inhibitors. (2013) (0)
- Mutagenic effect of chemotherapy on sperm DNA and implications for family planning (2022) (0)
- How I Treat How I treat smoldering multiple myeloma (2014) (0)
- Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma (2023) (0)
- Timing the initiation of multiple myeloma (2020) (0)
- O-307 Permethrin use and circulating immunologic markers: a longitudinal investigation in the Biomarkers of Exposure and Effect in Agriculture study (2021) (0)
- Treatment Outcomes in Monoclonal Immunoglobulin Deposition Disease (MIDD): A Two Center Experience (2018) (0)
- Impact of rare structural variant events in newly diagnosed multiple myeloma (2022) (0)
- Practice Patterns with Focal Progression on Daratumumab Therapy (2019) (0)
- The Role of 18f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) (2020) (0)
- Dietary Pattern and Risk of Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study (2016) (0)
- Biomarker to change Therapy MRD/Imaging vs FISH/Age - in Favor of MRD/Imaging (2015) (0)
- undetermined significance in Sweden first-degree relatives of 4458 patients with monoclonal gammopathy of Risk of plasma cell and lymphoproliferative disorders among 14621 (2013) (0)
- development of early treatment strategies smoldering multiple myeloma (SMM): novel biological insights and Monoclonal gammopathy of undetermined significance (MGUS) and (2013) (0)
- A prospective clinical study evaluating current models for risk of progression from smoldering multiple myeloma (SMM) to multiple myeloma (MM). (2012) (0)
- Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients (2019) (0)
- Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a "Spike-in" Clonal Sequence (2019) (0)
- Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study (2022) (0)
- Evidence of Improved Knowledge and Skills Among Hematologists/Oncologists Participating in Online CME-Certified Activities (2021) (0)
- veterans in the United States and subsequent multiple myeloma among African American and white Risk of monoclonal gammopathy of undetermined significance (MGUS) (2013) (0)
- A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea (2022) (0)
- Biological determinants of health disparities in multiple myeloma (2018) (0)
- immune- r elated and i nflammatory c onditions and r isk of l ymphoplasmacytic l ymphoma or Waldenström Macroglobulinemia (2010) (0)
- study of 9,729 patients diagnosed in Sweden 1973-2005 Improved patient survival for acute myeloid leukemia: A population-based (2013) (0)
- Myeloma precursor disease (MGUS) among rescue and recovery workers exposed to the World Trade Center disaster (2022) (0)
- Advances in MGUS diag no sis, risk strat i fi ca tion, and man age ment: intro duc ing myeloma-defi ning genomic events (2021) (0)
- HEPATOCELLULAR CARCINOMA New Therapies and Potential Biomarkers for Hepatocellular Carcinoma (0)
- Familial characteristics of Waldenström's macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL): A population-based study in Sweden (2008) (0)
- Family History of Venous Thromboembolism As a Risk Factor for Thrombosis in Multiple Myeloma Patients: A Population-Based Study, (2011) (0)
- Abstract 5746: Circulating cytokine levels, Epstein-Barr viremia and risk of AIDS-related non-Hodgkin lymphoma (2010) (0)
- Paradoxical role of the 19 S proteasomal regulator 1 Paradoxical resistance of multiple myeloma to proteasome inhibitors 1 by decreased levels of 19 S proteasomal subunits 2 3 (2015) (0)
- The Impact of Fractures on Survival in Multiple Myeloma: Results from a Population-Based Study (2018) (0)
- Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) after Multiple Myeloma: Assessment of Risk Factors (2017) (0)
- P-178: A pilot plant based dietary intervention in MGUS and SMM is feasible and associated with reduction in insulin and leptin levels (2022) (0)
- Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study (2022) (0)
- Gain of Chromosome 1q Portends Worse Prognosis in Multiple Myeloma Patients Treated with Novel Agent Based Induction Regimens Even after Autologous Transplantation (2015) (0)
- Abstract 5747: Chemotherapy-related mutational signatures reveal the origins of therapy-related myeloid neoplasms (2022) (0)
- Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma (2012) (0)
- Familial patterns of hematologic precursors. (2021) (0)
- hematopoietic cell transplantation Risk factors for lymphoproliferative disorders after allogeneic (2013) (0)
- Next-Generation Sequencing-Based Assay Shows High Clonal Characterization Success Rate for Plasma Cell Neoplasms, and Concordance with Flow Cytometry in Minimal Residual Disease Detection (2018) (0)
- Immunophenotypic profiles of plasma cells and tumor burden in patients with smoldering myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS). (2014) (0)
- Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma (2018) (0)
- Gain of Chromosome 1q Portends Worse Prognosis in Multiple Myeloma Patients Treated with Novel Agent Based Induction Regimens Even after Autologous Transplantation (2015) (0)
- Continuous Mobile Wearable Bio-Monitoring of Newly Diagnosed Multiple Myeloma Patients Undergoing Initial Chemotherapy (2018) (0)
- Patterns of autoimmunity and subsequent solid tumors among 4.5 million U.S. veterans (2008) (0)
- Minimal Residual Disease (MRD) Detection By Deep Sequencing In Newly Diagnosed Multiple Myeloma Patients Treated With Carfilzomib, Lenalidomide and Dexamethasone (2013) (0)
- A case study progression to multiple myeloma. (2010) (0)
- Novel Quadruplets and the Age of Immunotherapies in the Treatment of Newly Diagnosed Multiple Myeloma. (2022) (0)
- MRD-driven multiple myeloma treatment: next step forward (2020) (0)
- Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study (2023) (0)
- Mytype: A Capture Based Sequencing Approach to Detect Somatic Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma (2018) (0)
- Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures. (2022) (0)
- Obesity and Risk of Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study (2014) (0)
- A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study) (2020) (0)
- Immunophenotypic Evidence for Reactive Polyclonal Marrow Plasmacytosis in Multiple Myeloma Patients Receiving Long-Term Lenalidomide Therapy (2016) (0)
- Abstract 5472: Systems pharmacogenomics approach identifies synergistic molecular action of combined MTOR/HDAC inhibition on MYC (2014) (0)
- Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma (2008) (0)
- Depth of Response and Outcomes by Initial Therapy Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma (2019) (0)
- Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin (2022) (0)
- Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: A systematic review and meta-analysis of the literature. (2013) (0)
- 'Hepatitis B and C virus in patients with Non-Hodgkin lymphoma' (2007) (0)
- Early life dietary pattern and risk of monoclonal gammopathy of undetermined significance (2017) (0)
- Plasma Cell Myeloma and Plasma Cell Disorders (2017) (0)
- P-152: Providing nutritional guidance for patients with plasma cell disorders – a missed opportunity for hematologists and oncologists? (2021) (0)
- Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma (2022) (0)
- Improvement of Response for Multiple Myeloma patients on Lenalidomide Maintenance after Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) (2017) (0)
- Survival patterns among chronic lymphocytic leukemia and other lymphoma patients with family history of lymphoma (2007) (0)
- mantle cell lymphoma Mutated VH genes and preferential VH3-21 use define new subsets of (2013) (0)
- Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study (2022) (0)
- Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre‐ibrutinib era: A population‐based study (2021) (0)
- Multiple Myeloma Patients With Prior Knowledge Of MGUS Have a Better Survival Compared To Multiple Myeloma Patients Without Prior Knowledge Of MGUS (2013) (0)
- The kinetics and reproducibility of 18F-Sodium Fluoride (NaF) PET imaging (2012) (0)
- Plasma Protease-Mediated Metabolism of Carfilzomib and Its Implications on Clinical Effects and Side Effects (2014) (0)
- Risk and Cause of Death in 9,563 Patients Diagnosed with Myeloproliferative Neoplasms in Sweden Between 1973 and 2005, (2011) (0)
- V(D)J Sequence Capture for DNA-Based Minimal Residual Disease Detection in Multiple Myeloma (2018) (0)
- Whole Genome Sequencing of Extramedullary Myeloma Autopsy Tumors Reveals a Genomic Portrait at Culmination of Clonal Convergence (2018) (0)
- Impact Of History Of Autoimmune Disease On Survival In Multiple Myeloma and Monoclonal Gammopathy Of Undetermined Significance: A Population-Based Study (2013) (0)
- Abstract 4734: Genes cooperatively downregulated by combined mTOR/histone deactylase (HDAC) inhibition are overexpressed in myeloma patients with lower survival (2012) (0)
- Monoclonal Gammopathy of Undetermined Significance (2018) (0)
- Re: Risk of malignancy associated with Lyme disease: Still up in the air (2012) (0)
- A109 Improved Survival in Younger Patients with Multiple Myeloma: A Population-Based Study from Malmö, Sweden (2009) (0)
- MULTIPLE MYELOMA : FROM THE BENCH TO BEDSIDE Smoldering multiple myeloma (2015) (0)
- Author Correction: Prevalence of smoldering multiple myeloma based on nationwide screening. (2023) (0)
- Cancer incidence among pesticide applicators exposed to permethrin in the Agricultural Health Study - abstract (2009) (0)
- P-047: ADVANCE multicenter clinical trial: MRD-driven therapy in newly diagnosed multiple myeloma patients (2022) (0)
- Immune-Related and Inflammatory Conditions Likely Play a Role in the Development of Lymphoplasmacytic Lymphoma/Waidenstrom's Macroglobulinemia. (2008) (0)
- Antibody Response to Pneumococcal Polysaccharide Vaccination Predicts Pneumococcal Disease in Splenectomized Patients with Hematological Diseases. (2004) (0)
- Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms. (2023) (0)
- Abstract 369: Role of bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. (2013) (0)
- Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells (2021) (0)
- Cure with heart in mind! (2021) (0)
- Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma (2019) (0)
- consistently precedes multiple myeloma: a prospective study Monoclonal gammopathy of undetermined significance (MGUS) (2013) (0)
- mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies (2021) (0)
- Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population‐based study (2019) (0)
- Prospective comparison of fine-needle aspiration cytology (FNAC) and histopathology in the diagnosis and subclassification of primary lymphomas (2000) (0)
- Sa1251 Increased Mortality Among Men Aged 50 Years Old or Older With Elevated IgA Anti-Tissue Transglutaminase Antibodies: NHANES III 1988-1992 Follow-up Study (2013) (0)
- TreatmentWith Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in PatientsWith Smoldering or Newly DiagnosedMultipleMyeloma (2015) (0)
- Serum protein markers of clonal heterogeneity in myeloma. (2017) (0)
- Exposure to common community acquired infections associated with increased risk of multiple myeloma (2013) (0)
- Improved Prognosis in Multiple Myeloma-a Population Based Study on 13,376 Patients Diagnosed in Sweden 1973–2001. (2004) (0)
- diagnosis of chronic lymphocytic leukemia: a prospective study Evidence of serum immunoglobulin abnormalities up to 9.8 years before (2013) (0)
- Increased risk of monoclonal gammopathy of undetermined significance (MGUS) and lymphoid tumors among first-degree relatives of MGUS cases (2008) (0)
- Altered cytokine profiles in multiple myeloma (MM) and precursor disease: Predictors of progression and potential targets for treatment. (2013) (0)
- undetermined significance in the Agricultural Health Study Pesticide exposure and risk of monoclonal gammopathy of (2014) (0)
- Abstract 2217: A systems pharmacogenomic approach to identify synergistic molecular mechanisms of combined mTOR/HDAC inhibition. (2013) (0)
- Prevalence of smoldering multiple myeloma based on nationwide screening (2023) (0)
- Efficacy and Risk Factors Analysis of Upfront Autologous Stem Cell Mobilization Using Plerixafor and Granulocyte-Colony Stimulating Factor (GCSF) in Patients with Multiple Myeloma (2014) (0)
- 970 PAIN FOLLOWING BONE MARROW ASPIRATION IN ADULTS (2006) (0)
- Comment on Hjalgrim et al , page 2059 No CLL transmission through blood transfusion (2015) (0)
- Time to Relapse and the Patterns of Relapse Are Prognostic for Post-Relapse Survival after CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma (2020) (0)
- B-cell maturation antigen expression across hematologic cancers: a systematic literature review (2020) (0)
- Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort (2022) (0)
- Abstract 802: Cytokine profiles in bone marrow supernatant and peripheral blood of patients with multiple myeloma and Waldenström's macroglobulinemia (2011) (0)
- OAB-014: Chemotherapy signatures reveal the evolutionary history of post-melphalan myeloid neoplasm (2022) (0)
- Copy number signatures predict chromothripsis and associate with poor clinical outcomes in patients with newly diagnosed multiple myeloma (2020) (0)
- Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance–reply–I (2008) (0)
- Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort (2022) (0)
- Success of Online Curriculum-Based Education in the Management of Multiple Myeloma and Continuing Gaps Among Hematologists/Oncologists (2015) (0)
- List of Contributors (2019) (0)
- Autologous Hematopoietic Stem Cell Transplantation Overcomes Primary Refractory Disease in Multiple Myeloma Patients Treated with Novel Agents (2015) (0)
- Tracking the Earliest Genomic Events in Multiple Myeloma Life-History (2022) (0)
- Pretreatment Plasma Cell Proteasome Levels Predict Responses To Treatment With Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed By Lenalidomide Extended Dosing (CRd-R) In Newly Diagnosed Multiple Myeloma Patients (2013) (0)
- A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study (2021) (0)
- Biologic variations of plasma cells in the bone marrow of smoldering multiple myeloma (SMM) and multiple myeloma (MM) patients: Multiple biopsies in the same patient. (2013) (0)
- Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study (2022) (0)
- Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations (2022) (0)
- Author response: Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits (2015) (0)
- An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma (2019) (0)
- Progression From Precursor Disease to Multiple Myeloma—Reply (2011) (0)
- Abstract 5850: Nrf2-mediated oxidative stress response is altered during acquired resistance to the proteasome inhibitor, oprozomib, in multiple myeloma (2018) (0)
- Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study (2011) (0)
- Measurement of Serum microRNAs in US Veterans with Monoclonal Gammopathy of Undetermined Significance (2018) (0)
- The Mutagenic Impact of Radiotherapy in Multiple Myeloma (2022) (0)
- Next Questions: Multiple Myeloma (2021) (0)
- Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients (2022) (0)
- Melphalan Flufenamide: a Peptide-Drug Conjugate for the Treatment of Multiple Myeloma (2021) (0)
- Series of Hairy Cell Leukemia Patients with Co-Existent Plasma Cell Disorders (2014) (0)
- Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma (2020) (0)
- Re-vaccination following Autologous Hematopoietic Stem Cell Transplantation is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance (2019) (0)
- Diagnosed with myeloma before age 40. (2021) (0)
- Duration of Post-Autologous Hematopoietic Cell Transplant Anemia and Thrombocytopenia Are Associated with Prolonged Hospital Length-of-Stay for Multiple Myeloma Patients (2020) (0)
- Mass SpectrometryeBased Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma (2020) (0)
- Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens (2022) (0)
- Diagnostic and prognostic studies in Hodgkin's lymphoma with special reference to the elderly (2002) (0)
- Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM) (2022) (0)
- Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study (2010) (0)
- Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy (2022) (0)
- Racial disparities in incidence and survival among 37,977 blacks and whites with multiple myeloma. (2010) (0)
- Individualized Multidrug Resistance In Acute Myeloid Leukemia (2010) (0)
- Multiple Myeloma Summit In this review : Real-world MM outcomes in Australasia : optimising treatment – (2018) (0)
- Abstract C111: Genes cooperatively targeted by combined mTOR/histone deactylase (HDAC) inhibition are predictive of increased multiple myeloma patient survival. (2011) (0)
- P-046: Maintenance therapy cessation for patients with three-year sustained MRD negative remissions: initial results from a phase II study (2022) (0)
- Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies (2022) (0)
- Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM) (2021) (0)
- Abstract 934: A pooled investigation of circulating adiponectin levels and risk of multiple myeloma (2015) (0)
- Reply to bibas et Al. (2013) (0)
- Large granular lymphocyte (LGL) subsets in smoldering multiple myeloma (SMM): Immunophenotypic profiles that predict progression to multiple myeloma (MM). (2014) (0)
- Role of MRD as Prognostic Indicator, Clinical Trial Endpoint for Multiple Myeloma (2019) (0)
- A Phase 1b Study Investigating Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma (2016) (0)
- CHALLENGES IN THE MANAGEMENT OF HIGH-RISK MULTIPLE MYELOMA (2023) (0)
- Safety and Efficacy of Re-Immunization with Inactivated Vaccines in Multiple Myeloma Patients on Lenalidomide Maintenance Following Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) (2017) (0)
- Synthesis, preclinical analysis, and first-in-human phase I imaging of 89Zr-DFO-daratumumab for CD38 targeted imaging of myeloma (2019) (0)
- Monoclonal Gammopathies (2019) (0)
- Dynamic monitoring of minimal residual disease reveals its superior prognostic significance in multiple myeloma (2019) (0)
- Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure! (2022) (0)
- Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients. (2021) (0)
- FDA Analysis: Impact of Body Mass Index (BMI) on Outcomes in Relapsed-Refractory Multiple Myeloma (2019) (0)
- The Genomic Landscape of Waldenström Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations (2021) (0)
- Polyclonal Hypergammaglobulinemia in a Randomized Sample of Ghanaian Adult Males. (2007) (0)
- Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Commentary (2008) (0)
- [In the air force mistakes are converted into knowledge. When will the health care deal with safety issues seriously?]. (2001) (0)
- Enzymatic Activities Of Circulating Plasma Proteasomes (cProt) In Newly Diagnosed Multiple Myeloma (NDMM) Patients Undergoing Treatment With Carfilzomib, Lenalidomide and Dexamethasone (CRd) (2013) (0)
- Vκ*MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma (2022) (0)
- Multiomic Mapping of Copy Number and Structural Variation on Chromosome 1 (Chr1) Highlights Multiple Recurrent Disease Drivers (2021) (0)
- Brief report Infection in infancy and subsequent risk of developing lymphoma in children and young adults (2011) (0)
- Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures (2021) (0)
- Patterns of Venous Thromboembolism (VTE) Following Monoclonal Gammopathy of Undetermined Significance (MGUS) and Multiple Myeloma (MM) among 4 Million U.S. Veterans. (2006) (0)
- Association of Patient Activity Bio-Profiles with Health-Related Quality of Life: A Prospective Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients (2022) (0)
- Chronic Cyclic Nonnephrogenic Magnesium Depletion without Losses (2012) (0)
- Abstract PR6: A cooperative molecular response to combined mTOR/HDAC inhibition revealed by transcriptional co-expression analysis (2012) (0)
- PB2155 ONLINE CME SIGNIFICANTLY IMPACTS MULTIPLE MYELOMA CLINICIANS: EXPERIENCE FROM A MULTI-YEAR CURRICULUM WITH 33,699 LEARNERS (2019) (0)
- Peripheral Neuropathy Is Associated with an Increased Risk of Fractures in Individuals with Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study Including 15,351 MGUS Cases (2018) (0)
- Questions from the Community Clinical Investigators Provide Their Perspectives on Challenging Issues and Ongoing Research in the Management of Multiple Myeloma (2016) (0)
- 675 Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapy (2021) (0)
- Multiple myeloma and comorbidity: a population-based study (2019) (0)
- [Medical IT progress in American health care]. (2002) (0)
- Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. (2020) (0)
- of undetermined significance among black and white women Obesity is associated with an increased risk of monoclonal gammopathy (2013) (0)
- Increased Bone Marrow Plasma Cells at Diagnosis Predicts Overall Mortality in AL Amyloidosis Patients Undergoing Risk-Adapted Stem Cell Transplant (2014) (0)
- Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials (2015) (0)
- Future prospects of chimeric antigen receptor T‐cell therapy for multiple myeloma (2020) (0)
- 3.16 Increased Incidence of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Patients with Merkel Cell Carcinoma in Israel (2011) (0)
- Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls (2020) (0)
- Altered Plasma Cell Characteristics in Smoldering Myeloma and MGUS Patients with Preceding Immune-Related Conditions (2012) (0)
- Patterns of Monoclonal Immunoglobulins and Serum Free Light Chains Are Significantly Different in African-American Compared to Caucasian MGUS Patients. (2009) (0)
- Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma (2019) (0)
- Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ola Landgren?
Ola Landgren is affiliated with the following schools:
